ResearcherUniversity of PennsylvaniaNo recent work listed
Jacob Ezra Shabason
Matched on ORCID iD 0000-0002-1880-1207; OpenAlex author ID A5049597776. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper
Papers 2
- Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000854↗
- A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00280-018-3519-6↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- John Peter Plastaras · 2 shared papers, 2018–2021 · strength 0.17
- Paper Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreat… DOI 10.1097/coc.0000000000000854↗
- Paper A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline … DOI 10.1007/s00280-018-3519-6↗
- Edgar Ben‐Josef · 2 shared papers, 2018–2021 · strength 0.17
- Paper Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreat… DOI 10.1097/coc.0000000000000854↗
- Paper A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline … DOI 10.1007/s00280-018-3519-6↗
- Jeffrey A. Drebin · 2 shared papers, 2018–2021 · strength 0.17
- Paper Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreat… DOI 10.1097/coc.0000000000000854↗
- Paper A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline … DOI 10.1007/s00280-018-3519-6↗
- James M. Metz · 2 shared papers, 2018–2021 · strength 0.17
- Paper Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreat… DOI 10.1097/coc.0000000000000854↗
- Paper A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline … DOI 10.1007/s00280-018-3519-6↗
- Mark H. O’Hara · 2 shared papers, 2018–2021 · strength 0.17
- Paper Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreat… DOI 10.1097/coc.0000000000000854↗
- Paper A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline … DOI 10.1007/s00280-018-3519-6↗
- Kim A. Reiss · 2 shared papers, 2018–2021 · strength 0.17
- Paper Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreat… DOI 10.1097/coc.0000000000000854↗
- Paper A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline … DOI 10.1007/s00280-018-3519-6↗
- Adham Sean Bear · 1 shared paper, 2021 · strength 0.11
- William Tristram Arscott · 1 shared paper, 2021 · strength 0.11
- Stuti G. Shroff · 1 shared paper, 2021 · strength 0.11
- Peter James O'Dwyer · 1 shared paper, 2018 · strength 0.06
- Charles M. Vollmer · 1 shared paper, 2018 · strength 0.06
- Nirag Chandrakant Jhala · 1 shared paper, 2018 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.